Faricimab Could Save Injections for AMD and DME medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Activity
Retina Forum® 2021: Meeting the Vision of Reduced Treatment Burden in Neovascular Retinal Diseases - Session on Extending the Duration of Therapy
Educational Tools
Activity
Retina Forum® 2021: Meeting the Vision of Reduced Treatment Burden in Neovascular Retinal Diseases - Session on Extending the Duration of Therapy
Educational Tools
Certificate
Retina Forum® 2021: Meeting the Vision of Reduced Treatment Burden in Neovascular Retinal Diseases - Session on Extending the Duration of Therapy
This activity is supported by an educational grant from Genentech, Inc.
1.00 CME 60
MINS
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Share this article
LAS VEGAS, March 17, 2021 /PRNewswire/ DelveInsight s
Wet Age-Related Macular Degeneration (Wet AMD) Market report provides a thorough comprehension of the Wet Age-Related Macular Degeneration, historical and forecasted epidemiology, and the Wet AMD market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan]. The Wet Age-Related Macular Degeneration market report also proffers an analysis of recent Wet AMD treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
Some of the vital points of the
The introduction of Anti-vascular endothelial growth factor (VEGF) as a standard Wet AMD treatment has led to a significant improvement in patients prognosis, allowing recovery and maintenance of visual function in the vast majority of cases.
Global Diabetic Retinopathy Drug Forecast and Market Analysis to 2029
ResearchAndMarkets.com s offering. Currently, only severe forms of diabetic retinopathy such as PDR and severe NPDR are managed with pharmacotherapy. The standard of care for DME and RVO are anti-angiogenic agents which inhibit vascular endothelial growth factor (VEGF).
The most frequently used anti-VEGF drugs are Roche/Genentech s humanized antibodies Lucentis (ranibizumab) and Avastin (bevacizumab), and Bayer/Regeneron s fusion protein Eylea (aflibercept). Angiotensin converting enzyme (ACE) inhibitors can be used to treat patients with comorbid hypertension and diabetic retinopathy, while corticosteroids Alimera s Iluvien (fluocinolone acetonide), Allergan s Ozurdex (dexamethasone), and MaQaid (triamcinolone acetonide) can be used to treat people with RVO.